Quantify Research

Last week the team came together to give the office plants some much needed TLC. Turns out there are a fair few green fingers at Quantify! 🌿 Whilst we might not be adding gardening to our service offering any time soon, we hope that visitors to the Stockholm office will enjoy our jungle of plants just as much as we do. 🌻 Quantify Research [email protected] www.quantifyresearch.com

We're #hiring a new Finnish speaking Senior Research Analyst in to join our team in Helsinki. Apply today or share this post with your network. Quantify Research [email protected] www.quantifyresearch.com

📢 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲’𝐬 Mathias Lilja 𝐚𝐧𝐝 Johan Mesterton 𝐚𝐫𝐞 𝐜𝐨-𝐚𝐮𝐭𝐡𝐨𝐫𝐬 𝐨𝐧 𝐚 𝐧𝐞𝐰 𝐬𝐭𝐮𝐝𝐲 𝐨𝐧 𝐜𝐲𝐭𝐚𝐫𝐚𝐛𝐢𝐧𝐞 𝐝𝐨𝐬𝐢𝐧𝐠 𝐟𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐬𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐚𝐧𝐝 𝐡𝐢𝐠𝐡-𝐫𝐢𝐬𝐤 𝐀𝐌𝐋 𝐮𝐬𝐢𝐧𝐠 𝐚 𝐬𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐚𝐫𝐦 𝐬𝐭𝐮𝐝𝐲 𝐝𝐞𝐬𝐢𝐠𝐧 Since the 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). Our latest research at Quantify aimed to assess if higher cytarabine dosing in induction may provide a benefit in older patients with secondary and high-risk AML compared with the standard 7 + 3 regimen. To address this question, we collaborated with national clinical experts to leverage a synthetic control arm approach, combining unique data from the Swedish AML registry, including granular information on patient characteristics, treatments, and outcomes, with clinical trial data from the US and Canada. This study fills an important gap in the evidence base and offers new insights into treatment strategies for this vulnerable patient population. 🆕 What’s New? Quantify's recent study compared two key treatment protocols: ·      Standard 7+3 Regimen: 100 mg/m² cytarabine via continuous infusion for 7 days, plus 60 mg/m² daunorubicin for the first 3 days. ·      Swedish Standard-of-Care:1g/m² cytarabine twice daily for 7 days, along with 60 mg/m² daunorubicin administered in eight-hour infusions for the first 3 days. 🔍 Key Strength: A key challenge in any study of drug effectiveness—particularly when using external comparators—is ensuring that the study groups have similar characteristics. This study ensured comparability by aligning the Swedish AML registry patients with the trial’s eligibility criteria and through propensity scoring, including age, sex, and indicators of disease activity as matching variables. 📊 Key Findings: Our results suggest that intensified cytarabine dosing during induction is feasible also in high-risk older AML patients without increased early mortality and with beneficial long-term survival. 🤝 Connect with us: With extensive experience in conducting rigorous observational studies in pharmacoepidemiology, Quantify is your trusted partner for impactful research. Reach out to discuss how we can support your next project! Head over to our website for a link to the full article! https://lnkd.in/dnb2Q5Ch Quantify Research [email protected] www.quantifyresearch.com

𝐏𝐫𝐨𝐮𝐝 𝐭𝐞𝐚𝐦 𝐦𝐨𝐦𝐞𝐧𝐭 🌟 Last week a whooping 3 teams of Quantify Research colleagues took part in the annual Convini relay race in Stora Skuggan in Stockholm - our biggest turnout yet! A relay race truly embodies what we at Quantify are all about as you can't complete a relay without a strong team that works well together 🙌 Well done to everyone who took part! Kelsi Smith, Nicholas Norton, Jonas Banefelt, Mathias Lilja, Béranger Lueza, Alexandra Cooper, Fredrik Borgström, Linnea Oldsberg, Marcelina Kądziela, Liina Salovaara, Helena Skröder Löveborn, Ana Buzatu, Kirk Geale Quantify Research [email protected] www.quantifyresearch.com

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐟𝐨𝐫 𝐭𝐡𝐨𝐬𝐞 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐭𝐨 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 𝐭𝐡𝐞𝐢𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐜𝐜𝐞𝐬𝐬 𝐚𝐧𝐝 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞 (𝐑𝐖𝐄) 𝐞𝐟𝐟𝐨𝐫𝐭𝐬 𝐢𝐧 𝐅𝐢𝐧𝐥𝐚𝐧𝐝! Our capabilities have significantly expanded, allowing us to offer comprehensive support for your Finnish data and access needs. As the leading provider of Nordic RWE and market access services, we’ve strengthened our Finnish presence to deliver: ▪ End-to-end RWE including patient-level data access, biobanks, Findata permits, statistical analyses, reporting, manuscripts, and other medical communications ▪ Economic modelling, reimbursement dossiers, and strategic support to ensure your product reaches patients in need, through PPB or hospital channels ▪ Expert medical writing, systematic literature reviews, and meta-analyses to make sense of the high volume of research and HTA decisions, to support internal decision making, medical teams, and create strong value messaging Quantify’s experts can help you align your Finnish strategy with a broader market access approach and put Finnish RWD in the context of other potential data sources globally. Ready to succeed in Finland and beyond? Get in touch with our local Finnish experts Ville Perälä and Katja Nolvi to discuss your current needs and priorities.   𝐉ä𝐧𝐧𝐢𝐭𝐭ä𝐯𝐢ä 𝐮𝐮𝐭𝐢𝐬𝐢𝐚 𝐧𝐢𝐢𝐥𝐥𝐞, 𝐣𝐨𝐭𝐤𝐚 𝐡𝐚𝐥𝐮𝐚𝐯𝐚𝐭 𝐭𝐞𝐡𝐨𝐬𝐭𝐚𝐚 𝐥ää𝐤𝐤𝐞𝐢𝐝𝐞𝐧 𝐦𝐚𝐫𝐤𝐤𝐢𝐧𝐨𝐢𝐥𝐥𝐞𝐩ää𝐬𝐲ä 𝐣𝐚 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞 (𝐑𝐖𝐄) -𝐭𝐮𝐭𝐤𝐢𝐦𝐮𝐬𝐭𝐚𝐚𝐧 𝐒𝐮𝐨𝐦𝐞𝐬𝐬𝐚! Resurssimme ovat laajentuneet Suomessa merkittävästi, joten voimme tarjota kattavan tuen RWE- ja Market Access-tarpeisiisi. Pohjoismaiden johtavana RWE- ja Market Access-palveluiden tarjoajana olemme vahvistaneet organisaatiotamme Suomessa tuottaaksemme: ▪ End-to-end RWE-projektit, mukaan lukien potilastason tietojen käyttö, biopankit, Findata-luvat, tilastolliset analyysit, raportointi, julkaisut ja muu lääketieteellinen viestintä ▪ Taloudellinen mallinnus, korvattavuushakemukset ja strateginen tuki sen varmistamiseksi, että tuotteesi tavoittaa sitä tarvitsevat potilaat, joko Hila- tai sairaalakanavan kautta ▪ Asiantuntevat lääketieteellisen kirjoittamisen palvelut, systemaattiset kirjallisuuskatsaukset ja meta-analyysit laajan tutkimustiedon ja HTA-päätösten ymmärtämiseksi. Näitä voitte käyttää sisäiseen päätöksentekoon, lääketieteellisten osastojen tukemiseksi ja vahvan arvoviestinnän luomiseksi Quantifyn asiantuntijat voivat auttaa sinua asettamaan suomalaisen Access-suunnitelmasi linjaan globaalin suunnitelmasi kanssa ja asettamaan suomalaisen RWD:n muiden mahdollisten tietolähteiden rinnalle maailmanlaajuisesti. Oletko valmis menestymään Suomessa ja sen ulkopuolella? Ota yhteyttä paikallisiin suomalaisiin asiantuntijoihimme Ville Perälä tai Katja Nolvi keskustellaksesi tämänhetkisistä tarpeistasi.

𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐆𝐲𝐥𝐟𝐢 Ó𝐥𝐚𝐟𝐬𝐬𝐨𝐧 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐈𝐜𝐞𝐥𝐚𝐧𝐝𝐢𝐜 𝐇𝐄𝐎𝐑 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Quantify Research is excited to announce a new partnership with Gylfi Ólafsson, an expert in the Icelandic health care system and RWD landscape.  Gylfi holds a PhD from Karolinska Institutet and has previously worked as health economist at Quantify Research and as the CEO of the Westfjords Healthcare Institution in Iceland. This collaboration extends Quantify’s truly unparalleled ability to offer Nordic HEOR services. In addition to our expertise, offices and local staff in Denmark, Norway, Finland and Sweden, we are now proud to offer our clients complementary insights and strategic advice for Iceland. Iceland also has a unique RWD offering of interest to both local and global pharma. Do you need Nordic-wide RWE, reimbursement, or strategic support? Get in touch with us to find out more! Quantify Research [email protected] www.quantifyresearch.com

𝐓𝐚𝐫𝐠𝐞𝐭 𝐭𝐫𝐢𝐚𝐥𝐬, 𝐜𝐨𝐧𝐟𝐨𝐮𝐧𝐝𝐢𝐧𝐠, 𝐚𝐧𝐝 𝐑𝐂𝐓𝐬: 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲'𝐬 𝐉𝐞𝐬𝐬𝐢𝐜𝐚 𝐘𝐨𝐮𝐧𝐠 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐦𝐨𝐝𝐞𝐫𝐚𝐭𝐢𝐧𝐠, 𝐭𝐞𝐚𝐜𝐡𝐢𝐧𝐠, 𝐚𝐧𝐝 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐢𝐧𝐠 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐭 𝐈𝐒𝐏𝐄 2024! Jessica Young is an affiliated researcher with the CAUSALab at Karolinska Institutet and will be presenting her work on extending randomized trial estimates to real-world settings and a Nordic collaboration aimed at improving care for patients with inflammatory bowel disease.   List of engagements: 𝐏𝐫𝐞-𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐂𝐨𝐮𝐫𝐬𝐞 𝐅𝐚𝐜𝐮𝐥𝐭𝐲: 𝐈𝐧𝐭𝐞𝐫𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐞𝐩𝐢𝐝𝐞𝐦𝐢𝐨𝐥𝐨𝐠𝐲: 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐔𝐧𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝 𝐂𝐨𝐧𝐟𝐨𝐮𝐧𝐝𝐞𝐫𝐬 – 𝐐𝐮𝐚𝐧𝐭𝐢𝐭𝐚𝐭𝐢𝐯𝐞 𝐁𝐢𝐚𝐬 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 Sun Aug 25 14.30   𝐏𝐨𝐬𝐭𝐞𝐫: 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐨𝐟 𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐁𝐨𝐰𝐞𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐢𝐧 𝐒𝐰𝐞𝐝𝐞𝐧 𝐚𝐧𝐝 𝐍𝐨𝐫𝐰𝐚𝐲, 1982-2016 Aug 26 Poster Session A   𝐎𝐫𝐚𝐥 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐌𝐨𝐝𝐞𝐫𝐚𝐭𝐨𝐫: 𝐂𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐘𝐨𝐮𝐫 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐒𝐭𝐮𝐝𝐲 𝐃𝐞𝐬𝐢𝐠𝐧 Mon Aug 26 17.15   𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐒𝐩𝐞𝐚𝐤𝐞𝐫: 𝐓𝐚𝐫𝐠𝐞𝐭 𝐓𝐫𝐢𝐚𝐥 𝐄𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞: 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐆𝐫𝐚𝐝𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐞𝐩𝐢𝐝𝐞𝐦𝐢𝐨𝐥𝐨𝐠𝐲 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐈𝐆𝐌𝐀 𝐜𝐨𝐧𝐬𝐨𝐫𝐭𝐢𝐮𝐦  Wednesday Aug 28 10.30   𝐎𝐫𝐚𝐥 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐫: 𝐄𝐱𝐭𝐞𝐧𝐝𝐢𝐧𝐠 𝐫𝐚𝐧𝐝𝐨𝐦𝐢𝐳𝐞𝐝 𝐭𝐫𝐢𝐚𝐥 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐬 𝐭𝐨 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐭𝐚𝐫𝐠𝐞𝐭 𝐩𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬: 𝐀𝐧 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐚 𝐧𝐞𝐬𝐭𝐞𝐝 𝐭𝐫𝐢𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐫𝐢𝐧𝐠 𝐚𝐧𝐭𝐢𝐜𝐨𝐚𝐠𝐮𝐥𝐚𝐧𝐭 𝐫𝐞𝐠𝐢𝐦𝐞𝐧𝐬 𝐟𝐨𝐫 𝐩𝐞𝐫𝐜𝐮𝐭𝐚𝐧𝐞𝐨𝐮𝐬 𝐜𝐨𝐫𝐨𝐧𝐚𝐫𝐲 𝐢𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧 Wednesday Aug 28 14.00   If you are attending ISPE, make sure to catch Jess in action and find out how we can contribute to your future projects. Get in touch with us to book a meeting! Quantify Research [email protected] www.quantifyresearch.com

𝐍𝐨𝐫𝐝𝐢𝐜 𝐝𝐚𝐭𝐚 - 𝐰𝐡𝐲 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐡𝐲𝐩𝐞? The Nordic region (often called Scandinavia) is home to some of the world’s best real-world data (RWD), driving the development of pharmaceuticals and medical devices. As high-quality RWD becomes increasingly important to regulators and payers, it is critical for real-world evidence (RWE) practitioners across the globe to develop a working knowledge of the region's data characteristics and ecosystem in order to interpret and deploy Nordic RWD. Quantify Research can help! Whether it is directly in dialogue with our Nordic-wide expert team, through our educational resources, or from actual examples of our Nordic research we would be happy to explore if these data are right for you. We don't want to brag, but we've completed more than 300 RWE projects and published more than 185 manuscripts - and we would love to use this knowledge and experience to support you and your organisation. Check out this infographic for a quick intro to what the Nordics have to offer. Quantify Research [email protected] www.quantifyresearch.com

𝐓𝐰𝐨 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐝𝐚𝐲𝐬 𝐨𝐟 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐰𝐨𝐫𝐤 𝐢𝐧 𝐇𝐞𝐥𝐬𝐢𝐧𝐤𝐢 𝐛𝐞𝐡𝐢𝐧𝐝 𝐮𝐬! So efficient in fact, that the only photo we managed to get of it all was the wonderful view of our dinner venue. :P Quantify has worked with Finnish data and access for years, but our new local team has already begun to expand and accelerate our services intended for our local and global partners. In Finland we are currently focused on: ·      Continuing the high-quality delivery of all our ongoing Finnish work ·      Partnering with local Finnish stakeholders ·      Catching up with current and future pharma colleagues ·      Finding great new colleagues   We would love to connect with you to see where we can help. Looking forward to what’s next on this exciting journey. Watch this space for more! Quantify Research [email protected] www.quantifyresearch.com

𝐀𝐬 𝐬𝐮𝐦𝐦𝐞𝐫 𝐢𝐬 𝐝𝐫𝐚𝐰𝐢𝐧𝐠 𝐭𝐨 𝐚 𝐜𝐥𝐨𝐬𝐞 𝐮𝐩 𝐡𝐞𝐫𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐧𝐨𝐫𝐭𝐡𝐞𝐫𝐧 𝐡𝐞𝐦𝐢𝐬𝐩𝐡𝐞𝐫𝐞, 𝐦𝐚𝐧𝐲 𝐨𝐟 𝐨𝐮𝐫 𝐜𝐥𝐢𝐞𝐧𝐭𝐬 𝐚𝐫𝐞 𝐛𝐚𝐜𝐤 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞𝐢𝐫 𝐯𝐚𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐢𝐭’𝐬 𝐭𝐢𝐦𝐞 𝐭𝐨 𝐬𝐡𝐚𝐫𝐩𝐞𝐧 𝐨𝐮𝐫 𝐩𝐞𝐧𝐜𝐢𝐥𝐬 𝐚𝐧𝐝 𝐨𝐩𝐞𝐧 𝐮𝐩 𝐨𝐮𝐫 𝐝𝐢𝐚𝐫𝐢𝐞𝐬. 📖 ✏ We have an exciting and action-packed fall ahead of us, including: 🌍 Growing our global service offering (including our newest office in Finland!) 💥 Annual September Kick-off 🤓 Leadership training for senior staff 🤝 A number of conferences, such as ISPOR EU, DIA RWE and AI in RWE (see you there!) 👩💻 Continuing our projects across many different disease areas If you (like us) are busy making plans for the coming months, we would be happy to have a chat about your current and upcoming priorities. Get in touch! Quantify Research [email protected] www.quantifyresearch.com